

Proposal for a MSc-Thesis Project and Plan of Work

Drug repurposing: Treatment of inflammatory diseases

Background: The ion channel ANO1 (TMEM16A) and the homologous protein ANO6 (TMEM16F) are members of a larger family of transmembraneous proteins (14). ANO1 and ANO6 are upregulated in tumors (9) and in inflamed tissues, like in inflammatory airway diseases such as chronic obstructive lung diseases, asthma, and Cystic fibrosis (1, 5, 7). It is also upregulated during bacterial infection (4). ANO1 may participate in the transition from inflammation to proliferation, which explains its strong impact in wound healing and tissue repair (10, 15, 18). ANO1 has a pronounced effect on intracellular Ca^{2+} signaling, similar to ANO6 (3). However, sustained large increases in intracellular Ca^{2+} can also lead to senescence or cell death (2, 6). Thus, it is not surprising that ANO1 and ANO6 can support both cell proliferation and cell death. ANO6 has been reported initially in the context of apoptosis, but is now also known to be activated during other forms of regulated cell death, such as necroptosis, pyroptosis and ferroptosis (8, 12, 13, 16, 17). Given the reported findings, it should be possible to interfere with inflammation, proliferation and cells death by inhibitors or activators of ANO1 and ANO6.

Therefore, the present MSc project will examine the role of ANO1 and ANO6 in pathological conditions. The goal is to identify compounds that act on ANO1 and ANO6, ideally in an ANO-subtype specific way. Chemicals or natural products that are already accepted for the treatment of disease will be preferred. This so-called repurposing approach (11) may lead much faster to an effective drug when compared to the classical drug development strategy.

Objective: To identify and examine the effect of chemical compounds that enhance or inhibit the activity of AnO1 or AnO6 in the context of inflammation, proliferation and cell death.

Methodology: This MSc project will make use of existing mouse models, which have been generated in our laboratory. These tissue specific mouse models can be further genetically modified to induce a knockout of ANO1 or ANO6 in specific tissues. Inflammation will be induced and the effect of ANO1 / ANO6 knockout and drug modifiers will be examined. Moreover, inflammatory *in vitro* models will be used to assess the effect of ANO1 / ANO6 – acting drugs on inflammation, proliferation or cell death.

A whole spectrum of methods and techniques is available and will be applied depending on their demand. Techniques range from genetic manipulation *in vitro* and *in vivo*, standard cell biological techniques, to a more specialized functional analysis.

SUPERVISORS

- Prof. Dr. Karl Kunzelmann, Dept. of Physiology, University of Regensburg, University street 31, 93051 Regensburg, Germany. Karl.Kunzelmann@ur.de
http://www.biologie.uni-regensburg.de/Physiologie/Kunzelmann/index_en.html
- Co-Supervisor: Prof. Dr. Margarida Amaral, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, University of Lisboa, (mdamaral@fc.ul.pt)

WORK PLACE

- Dept. of Physiology, University of Regensburg, Germany. The University is located in Regensburg/Bavaria, which is a relatively small city and old medieval town about 1 hour car drive north of Munich.

To cover costs for travel and housing in Regensburg, a fellowship will be provided.

Literature

1. **Benedetto R, Cabrita I, Schreiber R, and Kunzelmann K.** TMEM16A is indispensable for basal mucus secretion in airways and intestine. *FASEB J* 33: 4502-4512, 2019.
2. **Borahay MA, Kilic GS, Yallampalli C, Snyder RR, Hankins GD, Al-Hendy A, and Boehning D.** Simvastatin potently induces calcium-dependent apoptosis of human leiomyoma cells. *J Biol Chem* 289: 35075-35086, 2014.
3. **Cabrita I, Benedetto R, Fonseca A, Wanitchakool P, Sirianant L, Skryabin BV, Schenk LK, Pavenstadt H, Schreiber R, and Kunzelmann K.** Differential effects of anoctamins on intracellular calcium signals. *Faseb j* 31: 2123-2134, 2017.
4. **Caci E, Scudieri P, Di Carlo E, Morelli P, Bruno S, De F, I, Bragonzi A, Gianotti A, Sondo E, Ferrera L, Palleschi A, Santambrogio L, Ravazzolo R, and Galletta LJ.** Upregulation of TMEM16A Protein in Bronchial Epithelial Cells by Bacterial Pyocyanin. *PLoS ONE* 10: e0131775, 2015.

5. **Huang F, Zhang H, Wu M, Yang H, Kudo M, Peters CJ, Woodruff PG, Solberg OD, Donne ML, Huang X, Sheppard D, Fahy JV, Wolters PJ, Hogan BL, Finkbeiner WE, Li M, Jan YN, Jan LY, and Rock JR.** Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. *Proc Natl Acad Sci U S A* 109: 16354-16359, 2012.
6. **Jackisch C, Hahm HA, Tombal B, McCloskey D, Butash K, Davidson NE, and Denmeade SR.** Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. *Clinical cancer research : an official journal of the American Association for Cancer Research* 6: 2844-2850, 2000.
7. **Kondo M, Tsuji M, Hara K, Arimura K, Yagi O, Tagaya E, Takeyama K, and Tamaoki J.** Chloride ion transport and overexpression of TMEM16A in a guinea pig asthma model. *Clin Exp Allergy* 47: 795-804, 2017.
8. **Kunzelmann K.** Ion channels in regulated cell death. *Cell Mol Life Sci* 73: 2387-2403, 2016.
9. **Kunzelmann K, Ousingsawat J, Benedetto R, Cabrita I, and Schreiber R.** Growth and death by anoctamins. *Frontiers in neuroscience* 2019.
10. **Landen NX, Li D, and Stahle M.** Transition from inflammation to proliferation: a critical step during wound healing. *Cell Mol Life Sci* 73: 3861-3885, 2016.
11. **Miner K, Labitzke K, Liu B, Elliot R, Wang P, Henckels K, Gaida K, Elliot R, Chen JJ, Liu L, Leith A, Trueblood E, Hensley K, Xia X-Z, Homann O, Bennett B, Fiorino M, Whoriskey J, Yu G, Escobar S, Wong M, Born TL, Budelsky A, Comeau M, Smith D, Phillips J, Johnston JA, McGivern JG, Weikl K, Powers D, Kunzelmann K, Mohn D, Hochheimer A, and Sullivan JK.** The Anthelmintic Niclosamide And Related Compounds Represent Potent Tmem16a Antagonists That Fully Relax Mouse And Human Airway Rings. *Froniers in Pharmacology* 2019.
12. **Ousingsawat J, Cabrita I, Wanitchakool P, Sirianant L, Krautwald S, Linkermann A, Schreiber R, and Kunzelmann K.** Ca²⁺ signals, cell membrane disintegration, and activation of TMEM16F during necroptosis. *Cell Mol Life Sci* 2016.
13. **Ousingsawat J, Wanitchakool P, Schreiber R, and Kunzelmann K.** Contribution of TMEM16F to pyroptotic cell death. *Cell Death Dis* 9: 300, 2018.
14. **Pedemonte N, and Galletta LJ.** Structure and Function of TMEM16 Proteins (Anoctamins). *Physiol Rev* 94: 419-459, 2014.
15. **Ruiz C, Martins JR, Rudin F, Schneider S, Dietsche T, Fischer CA, Tornillo L, Terracciano LM, Schreiber R, Bubendorf L, and Kunzelmann K.** Enhanced Expression of ANO1 in Head and Neck Squamous Cell Carcinoma Causes Cell Migration and Correlates with Poor Prognosis. *PLoS ONE* 7: e43265, 2012.
16. **Schreiber R, Ousingsawat J, Wanitchakool P, Sirianant L, Benedetto R, Reiss K, and Kunzelmann K.** Regulation of TMEM16A/ANO1 and TMEM16F/ANO6 ion currents and phospholipid scrambling by Ca²⁺ and plasma membrane lipid *J Physiology (London)* 596: 217-229, 2018.
17. **Simoes F, Ousingsawat J, Wanitchakool P, Fonseca A, Cabrita I, Benedetto R, Schreiber R, and Kunzelmann K.** CFTR supports cell death through ROS-dependent activation of TMEM16F (anoctamin 6). *Pflugers Arch* 470: 305-314, 2018.
18. **Whitlock JM, Yu K, Cui YY, and Hartzell HC.** Anoctamin 5/TMEM16E facilitates muscle precursor cell fusion. *J Gen Physiol* 2018.